Aqua-Med Consulting S.R.L.

The research team at Aqua-Med Consulting S.R.L. is investigating innovative treatments for autoimmune conditions, aiming to lessen systemic inflammation and improve quality of life.

• Primary Sjögren’s disease
• Systemic sclerosis

Current studies assess the benefit of efgartigimod in reducing disease activity for Sjögren’s syndrome and explore BI 685509 as a strategy to preserve lung function and address multi‑organ involvement in systemic sclerosis.

In the musculoskeletal arena, the site focuses on chronic inflammatory joint disorders, seeking therapies that can halt disease progression and relieve pain.

• Axial spondyloarthritis

One trial evaluates the effectiveness of filgotinib in managing spinal inflammation and improving functional outcomes for patients with active axial spondyloarthritis.

Research efforts are directed toward disorders affecting the skin, vessels, and connective tissues, with the goal of discovering agents that modify disease pathways.

• Systemic sclerosis
• Primary Sjögren’s disease

Studies aim to evaluate how novel compounds can improve skin elasticity, reduce fibrosis, and mitigate systemic symptoms, thereby enhancing overall patient health.